Rib-X Pharmaceuticals, Inc. Appoints Dr. Joseph Amprey of MedImmune Ventures to Board of Directors
New Haven, Connecticut. September 2, 2008 — Rib-X Pharmaceuticals, Inc.,
a development stage company focused on the discovery and development of
novel antibiotics for the treatment of antibiotic resistant infections, today announced that
Joseph Amprey, M.D., Ph.D., has been appointed to the Company's Board of Directors,
succeeding David Mott. Mr. Mott, formerly with MedImmune and MedImmune Ventures, is
also continuing as an Independent Director of the Company. Rib-X's board now consists of
10 members.
"We are extremely pleased that Joe Amprey has joined the Rib-X Board," said Dr. Susan Froshauer, President and Chief Executive Officer, Rib-X. "Joe brings an impressive level of experience in the financial sector that will be crucial as the Company grows and continues to move products through the development pipeline. Additionally, we are most grateful to David for the commitment he has made to Rib-X since joining our board in 2007 and look forward to benefiting from his ongoing guidance."
Dr. Amprey is Senior Managing Director at MedImmune Ventures, a venture capital fund wholly owned by MedImmune, L.L.C. and he has primary responsibility for overseeing the fund's operations. He has been with MedImmune Ventures since 2006 and sits on the MedImmune Ventures investment committee, as well as on the boards of portfolio companies Synovex and NKT Therapeutics. Prior to joining MedImmune, Dr. Amprey worked at Carrot Capital HealthCare Ventures. He earned his M.D. and Ph.D. in Immunology from Cornell University in New York, and his B.A. in biochemistry from the University of Pennsylvania.
David Mott joined the Rib-X board in 2007. Mr. Mott was the Chief Executive Officer of MedImmune, a position he held from October 2000 until he departed the organization in July 2008. Mr. Mott joined MedImmune in 1992 as Vice President and held positions of increasing responsibility including Chief Financial Officer, Chief Operating Officer and President. He also founded MedImmune Ventures and served as Chairman of its Investment Committee. Prior to joining MedImmune, Mr. Mott was a Vice President in the Health Care Investment Banking Group at Smith Barney, Harris Upham & Co., Inc. Mr. Mott is a member of the Board of Directors of Shire plc and also serves on the Boards of Directors for the Biotechnology Industry Organization (BIO) and St. Albans School. He has previously served on the boards of Conceptis Technologies, Ambit Biosciences, the Technology Council of Maryland, MdBio and a number of non-profits. He attended Dartmouth College, where he holds a bachelor's degree in economics and government.
About Rib-X Pharmaceuticals
Rib-X Pharmaceuticals, Inc. is a product-driven small-molecule drug discovery and development company focused on developing and commercializing antibiotics to treat highly-resistant bacterial infections. Based in New Haven, Connecticut, the Company has raised over $170 million and has two programs, delafloxacin and radezolid, in advanced clinical trials. In addition, a preclinical program featuring an entirely new class of broad-spectrum antibiotics with the potential to treat even highly- resistant Gram-negative infections is scheduled to begin clinical trials in 2011.
Rib-X designs and develops novel small-molecule antibiotics by leveraging the Company's Nobel Prize- winning discovery platform to perform structure-based design and optimization. While many commercially valuable classes of antibiotics bind to the bacterial ribosome, including oxazolidinones, tetracyclines and macrolides, traditional antibiotic discovery relies heavily on serendipity. Rib-X's key competitive advantage is its proprietary understanding of ribosome structure, which enables it to generate antibiotics that overcome known resistance mechanisms and have broad-spectrum activity.
Rib-X's integrated research strategy combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, thereby allowing Rib-X to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinct new antibiotic classes.
"We are extremely pleased that Joe Amprey has joined the Rib-X Board," said Dr. Susan Froshauer, President and Chief Executive Officer, Rib-X. "Joe brings an impressive level of experience in the financial sector that will be crucial as the Company grows and continues to move products through the development pipeline. Additionally, we are most grateful to David for the commitment he has made to Rib-X since joining our board in 2007 and look forward to benefiting from his ongoing guidance."
Dr. Amprey is Senior Managing Director at MedImmune Ventures, a venture capital fund wholly owned by MedImmune, L.L.C. and he has primary responsibility for overseeing the fund's operations. He has been with MedImmune Ventures since 2006 and sits on the MedImmune Ventures investment committee, as well as on the boards of portfolio companies Synovex and NKT Therapeutics. Prior to joining MedImmune, Dr. Amprey worked at Carrot Capital HealthCare Ventures. He earned his M.D. and Ph.D. in Immunology from Cornell University in New York, and his B.A. in biochemistry from the University of Pennsylvania.
David Mott joined the Rib-X board in 2007. Mr. Mott was the Chief Executive Officer of MedImmune, a position he held from October 2000 until he departed the organization in July 2008. Mr. Mott joined MedImmune in 1992 as Vice President and held positions of increasing responsibility including Chief Financial Officer, Chief Operating Officer and President. He also founded MedImmune Ventures and served as Chairman of its Investment Committee. Prior to joining MedImmune, Mr. Mott was a Vice President in the Health Care Investment Banking Group at Smith Barney, Harris Upham & Co., Inc. Mr. Mott is a member of the Board of Directors of Shire plc and also serves on the Boards of Directors for the Biotechnology Industry Organization (BIO) and St. Albans School. He has previously served on the boards of Conceptis Technologies, Ambit Biosciences, the Technology Council of Maryland, MdBio and a number of non-profits. He attended Dartmouth College, where he holds a bachelor's degree in economics and government.
About Rib-X Pharmaceuticals
Rib-X Pharmaceuticals, Inc. is a product-driven small-molecule drug discovery and development company focused on developing and commercializing antibiotics to treat highly-resistant bacterial infections. Based in New Haven, Connecticut, the Company has raised over $170 million and has two programs, delafloxacin and radezolid, in advanced clinical trials. In addition, a preclinical program featuring an entirely new class of broad-spectrum antibiotics with the potential to treat even highly- resistant Gram-negative infections is scheduled to begin clinical trials in 2011.
Rib-X designs and develops novel small-molecule antibiotics by leveraging the Company's Nobel Prize- winning discovery platform to perform structure-based design and optimization. While many commercially valuable classes of antibiotics bind to the bacterial ribosome, including oxazolidinones, tetracyclines and macrolides, traditional antibiotic discovery relies heavily on serendipity. Rib-X's key competitive advantage is its proprietary understanding of ribosome structure, which enables it to generate antibiotics that overcome known resistance mechanisms and have broad-spectrum activity.
Rib-X's integrated research strategy combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, thereby allowing Rib-X to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinct new antibiotic classes.
| Public Relations |
|---|
|
Kari Watson
MacDougall BioMedical Communications 781-235-3060 kari@macbiocom.com |
| Investor Relations |
|
Sarah Cavanaugh
MacDougall BioMedical Communications 781-235-3060 scavanaugh@macbiocom.com |